Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In Leukemia, Myelodysplasia, Transplantation

Leukemia, Myelodysplasia, Transplantation for March/April 2019

Biomarker testing may transform treatment of acute GVHD,

Idelalisib shows long-term safety, efficacy for relapsed CLL,

Complementary medicine use common among patients on TKIs,

Model inspired by Netflix, Amazon may help guide MDS treatment,

Sorafenib plus GCLAM yielded 83% complete response rate in AML, MDS,

More must reads

Leukemia, Myelodysplasia, Transplantation for January/February 2019

CLL, GVHD may raise risk for skin cancer after allo-HCT,

Treosulfan may become standard in allo-HCT for AML/MDS,

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML,

More must reads

Leukemia, Myelodysplasia, Transplantation for September/October 2018

CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9

Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.

ALL complications carry cognitive risks, Cheung YT et al. JAMA Pediatr. 2018 Sep 24. doi:10.1001/jamapediatrics.2018.2500.

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004
More must reads

Leukemia, Myelodysplasia, Transplantation for July/August 2018

Vadastuximab talirine improves AML remission rates, Fathi AT et al. Blood. 2018 Jul 25. doi: 10.1182/blood-2018-03-841171.

ALL patients are not routinely getting appropriate IT MTX , Sommerfeld SA et al. EHA Congress, Abstract PS930.
More must reads

Leukemia, Myelodysplasia, Transplantation for May/June 2018

Added pomalidomide reduced risk of progression, death in myeloma, Richardson PG et al. ASCO 2018, Abstract 8001.
More must reads

Pages